PhRMA: Market overreacted to Obama plans

In another layer of support for President Obama's healthcare reform plans, PhRMA chief Billy Tauzin said drug companies won't lose even if universal healthcare ends up depressing pharma prices. That's because drugmakers would sell more of the lower-priced meds, making up in volume what they lose on price cuts. Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.